OncLive

OncLive has been a member of Linktree for 1 year and joined in February 2025. The social media accounts linked to from OncLive are: • Facebook • Instagram • YouTube • LinkedIn • X • Bluesky Besides social media accounts, onclive has populated their site with: • Breast Cancer Briefing with MinhTri Nguyen, MD • FDA Approves Lurbinectedin Plus Atezolizumab as First-Line Maintenance Therapy for ES-SCLC | OncLive • Oncology Conferences to Watch in the Second Half of 2025 • Real-World Evidence Complements and Contextualizes Randomized Clinical Trial Insights in Colorectal Cancer • FDA Approves Imlunestrant for ER+, HER2-Negative, ESR1-Mutated Metastatic Breast Cancer | OncLive • Advances in Targeted Therapies and ADCs in Gynecologic Cancer Are Highly Anticipated at the 2025 ESMO Congress | OncLive • OncLive - Clinical Oncology News, Cancer Expert Insights • From Growing Survivorship Programs to Practicing Self-Care: A Day in the Life With Oncologist Alicia Morgans, MD, MPH • ‎OncLive Insider - Apple • 4 Ways Oncologists Use Social Media to Debunk Myths and Dispel Misinformation • OncLive Insider - Android • FDA Approves TAR-200 in BCG-Unresponsive NMIBC With CIS • 🎙 Podcasts 🎙| Clinical Oncology News & Insights | OncLive • SOHO Spotlight: Hematologists Share Practice-Informing Insights From the 2025 Annual Meeting • Try Out Scout! • FDA Approves Selumetinib for Symptomatic Pediatric NF-1–Associated Inoperable Plexiform Neurofibromas • FLAURA-2 and HARMONi Trial Readouts Reinforce Importance of ‘Divide and Conquer’ Approach to Lung Cancer Care at WCLC 2025 • Experts Highlight Key Topics to Watch at the 22nd International Myeloma Society Annual Meeting • Advances in Surgical Approaches and Targeted Therapies Highlight Progress in Uterine Cancer | OncLive • Targeted Therapies Drive Demand for Comprehensive Biomarker Testing in NSCLC | OncLive • Inside the Most Anticipated Lung Cancer Abstracts: What to Expect From ESMO 2025 | OncLive • FDA Approves 3-Month Version of Leuprolide Mesylate for Advanced Prostate Cancer • Removal of REMS Requirements Improves Access to CAR T-Cell Therapy Across Hematologic Malignancies • Cellular Therapies Begin to Make Their Mark in Solid Tumors • Rising Incidences, Misconceptions, and Unmet Needs Warrant Awareness for Appendix Cancer • OncLive’s July EMA Regulatory Recap: Key EU Approvals in Oncology • FDA’s Published CRLs Deliver Insight Into the Drug Approval Process • FDA Grants Accelerated Approval to Zongertinib for Nonsquamous NSCLC With HER2 TKD Mutations • Minimally Invasive Surgery and Multidisciplinary Collaboration Improves Recovery Time in Lung Cancer • FDA’s ODAC Votes Against Risk:Benefit Profiles of Belantamab Mafodotin Combos in R/R Myeloma • Nuanced Biomarker Tests and Immunotherapy Strategies May Usher ASCO 2025 Data Into the Clinic • FDA Grants Accelerated Approval to Sunvozertinib for Metastatic NSCLC With EGFR Exon 20 Insertion Mutations • FDA Approves Oncomine Dx Express Test for Tumor Profiling and as Companion Diagnostic for Sunvozertinib in NSCLC • Ongoing Trials Aim to Remove Carboplatin from TCHP and Reduce Treatment Cycles in HER2+ Breast Cancer • FDA Approves Linvoseltamab for Relapsed/Refractory Multiple Myeloma • Subscribe to OncLive’s conference emails • Curiosity and Compassion Propel Lung Cancer Pioneer Ramalingam to TIME100 Health 2025 List • FDA Grants Accelerated Approval to Dato-DXd for EGFR+ NSCLC • Hematologists Highlight Notable Insights From the 2025 EHA Congress • ‎OncLive Insider App • OncLive App Info • FDA Approves Taletrectinib for ROS1+ Advanced NSCLC • FDA Approves Intravesical Mitomycin for Recurrent, Low-Grade, Intermediate-Risk NMIBC • FDA Declines to Expand Label for Talazoparib/Enzalutamide in mCRPC • FDA Approves Tafasitamab Plus Lenalidomide and Rituximab for R/R Follicular Lymphoma • Experts Underscore the Top Abstracts to Watch at the 2025 EHA Congress • ASCO Annual Meeting • BCG Shortage Warrants Treatment Shifts, New Treatment Strategies in Bladder Cancer • FDA’s ODAC Votes Against Risk/Benefit Profile of UGN-102 in Recurrent, Low-Grade, Intermediate-Risk NMIBC • FDA Votes Against Risk/Benefit Profile of Talazoparib Plus Enzalutamide for Non-HRR–Mutant mCRPC • Breast Cancer Experts Bookmark Top Abstracts to Watch at the 2025 ASCO Annual Meeting • Lung Cancer Experts Highlight the Most Anticipated Abstracts at the 2025 ASCO Annual Meeting • Hematology Experts Outline the Top Abstracts to Watch at the 2025 ASCO Annual Meeting • Experts Preview Key Presentations to Watch in Gynecologic Oncology at ASCO 2025 • Gastrointestinal Cancer Experts Spotlight the Most Exciting Abstracts Ahead of the 2025 ASCO Annual Meeting • Improved Public Awareness and Immunotherapy Drive Down Melanoma Mortality Amid Rising Incidences • Experts Spotlight Noteworthy GU Cancer Abstracts Ahead of the 2025 ASCO Annual Meeting • Oncology Experts Preview Top Abstracts From AUA 2025 • American Urological Association Annual Meeting • OncLive’s FDA Approval Report: The Regulatory Rundown for March 2025 • AYA Cancer Awareness Week: Patient Support, Multidisciplinary Care Are Key for Management of NETs • FDA Approves Pembrolizumab Plus Trastuzumab/Chemo for PD-L1+, HER2+ Gastric/GEJ Adenocarcinoma • OncLive’s FDA Approval Report: The Regulatory Rundown for February 2025 • Anal Cancer Awareness Day Q&A